4D Molecular Therapeutics Reports Q1 Results, Advances Clinical Programs

4D Molecular Therapeutics (NASDAQ:FDMT) reported strong financial results for the first quarter of 2026 and provided updates on its clinical trials. The company expects to fund operations through at least mid-2028 with $458 million in cash reserves, while advancing Phase 3 trials for gene therapy candidates targeting retinal diseases.

By Abdul Rahman Wed, May 20, 2026 at 3:36 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 12:36 UTC

Tickers: $FDMT

Topics: 4D Molecular Therapeutics FDMT stock gene therapy Phase 3 trials

Read the full article at Yahoo Finance

More World news

Marvell Technology Appoints Three Independent Directors Prior to Proposed Lumentum Acquisition Seeking Alpha · November 12, 2026, 14:35 UTC
M-tron Industries Reports Q3 2026 GAAP EPS Miss Amid Low Revenue Seeking Alpha · November 12, 2026, 14:37 UTC
Nexxen International Reports Q3 Earnings Beat with Revenue Growth and Increased EBITDA Seeking Alpha · November 12, 2026, 14:30 UTC
Brookfield Corporation Announces Quarterly Dividend of $0.07 Per Share Seeking Alpha · November 12, 2026, 14:30 UTC
Upwork Expands Restructuring Plan to Reduce Workforce by 37% Seeking Alpha · November 12, 2026, 14:34 UTC
Deswell Industries Reports First-Half Revenue of $33.02 Million Amid Segment Shifts Seeking Alpha · November 12, 2026, 14:35 UTC
Avicanna Reports Q3 Results with Positive Adjusted EBITDA and Reduced Operating Losses Seeking Alpha · November 12, 2026, 14:29 UTC
Bridgemarq Real Estate Services Announces Monthly Dividend of CAD 0.0125 per Share Seeking Alpha · November 12, 2026, 14:29 UTC
Natus Medical Expands Global Clinical Collaboration via New EMG and EEG Advisory Boards PR Newswire · November 12, 2026, 14:33 UTC
CoreWeave Reports Strong Third-Quarter Results Driven by AI Demand Motley Fool · November 12, 2026, 14:30 UTC